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Introduction
The term “autoinflammatory” appeared 
in the pages of Cell in the spring of 1999 
to denote an emerging family of clinical 
disorders characterized by episodes 
of seemingly unprovoked inflamma-
tion without high-titer autoantibodies or 
antigen-specific T lymphocytes (McDer-
mott et al., 1999). This proposed nomen-
clature was inspired by the discovery of 
dominantly inherited missense muta-
tions in TNFRSF1A, the gene encoding 
the 55 kDa tumor necrosis factor recep-
tor, in several families with prolonged 
fevers and severe localized inflam-
mation. Patients with this illness, now 
known as the TNF receptor-associated 
periodic syndrome (TRAPS), present 
with dramatic, sometimes month-long 
bouts of fever with sterile peritonitis, 
pleurisy, arthritis, migratory erythema, or 
periorbital edema. In some cases, renal 
failure develops due to the deposition of 
an acute-phase reactant, serum amyloid 
A (SAA), in the kidneys. Although TNF 
has pleiotropic effects on immune func-
tion, inducing leukocyte activation and 
cytokine secretion, expression of adhe-
sion molecules, and host resistance to 
intracellular pathogens, TRAPS patients 
do not usually manifest the self-reactive 
antibodies or T cells that are the hall-
marks of autoimmunity.
The discovery of TRAPS followed 
close on the heels of the positional 
cloning of another gene that when 
mutated causes familial Mediterranean 
fever (FMF), the first-recognized and 
still most common hereditary recurrent 
fever syndrome (International FMF Con-
sortium, 1997; French FMF Consortium, 
1997). FMF presents with a constella-
tion of serosal, synovial, and cutaneous 
inflammation similar to TRAPS and also 
lacks the cardinal features of autoim-
munity seen in diseases such as sys-
temic lupus erythematosus (SLE) and 
rheumatoid arthritis. The autoinflam-
matory terminology sought to provide a 
unifying concept for a newly recognized 
group of illnesses clinically distinct from 
the more well-studied autoimmune dis-
eases.
This formulation has proven to be a 
useful construct over the last decade, 
with the recognition of an ever-growing 
list of illnesses falling under the autoin-
flammatory rubric (Table 1) (Galon et al., 
2000; Masters et al., 2009). Four recur-
rent fever syndromes have been added 
to the list, including the recessively 
inherited hyperimmunoglobulinemia D 
with periodic fever syndrome (HIDS) and 
a spectrum of three illnesses of varying 
severity all caused by dominant or de 
novo mutations in a gene, NLRP3/CIAS1, 
encoding a critical activator of IL-1β orig-
inally termed cryopyrin (now NLRP3). At 
the milder end of the cryopyrinopathies, 
familial cold autoinflammatory syndrome 
(FCAS) is characterized by cold-induced 
episodes of fever and hives, whereas 
the most severe phenotype, neonatal-
onset multisystem inflammatory disease 
(NOMID; also known as chronic infan-
tile neurologic cutaneous and articular 
syndrome, or CINCA), manifests nearly 
continuous fevers, with a hive-like rash, 
overgrowth of the epiphyses of the long 
bones, and chronic aseptic meningitis 
that can cause blindness, progressive 
hearing loss, and mental retardation. The 
concept of autoinflammation has been 
extended to a number of clinical entities 
beyond the confines of the hereditary 
recurrent fever syndromes, including 
several Mendelian diseases, as well as 
disorders with a more complex (poly-
genic) mode of inheritance. The clinical 
scope of autoinflammatory conditions is 
now broad, encompassing syndromes 
that variously present with, among other 
things, serositis, pyogenic arthritis, pyo-
derma gangrenosum, granulomatous 
uveitis, crystalline arthritis, and certain 
forms of vasculitis.
The recognition of the distinction 
between autoimmune and autoinflamma-
tory diseases has paralleled advances in 
our understanding of the molecular and 
cellular basis of innate immunity. In the 
traditional autoimmune diseases like SLE, 
the adaptive immune system, driven by 
lymphocytes with antigen receptors that 
somatically rearrange and mutate, plays 
a decisive role in pathogenesis. In con-
trast, the autoinflammatory diseases are 
defined by their relative lack of evidence 
for adaptive immunity. Not surprisingly, 
the innate immune system, with its myel-
oid effector cells and germline receptors 
for pathogen-associated molecular pat-
terns and “danger signals,” predominates 
in the pathogenesis of these illnesses. 
The recognition of disease-associated 
mutations in NLRP3/CIAS1 (Hoffman et 
al., 2001; Aksentijevich et al., 2002; Feld-
mann et al., 2002) was particularly deci-
sive in drawing the connection between 
autoinflammatory disease and innate 
immunity, given that the encoded pro-
tein is the linchpin of the NLRP3 inflam-
masome—a molecular engine of the 
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Table 1. Clinical Classification of Selected Autoinflammatory Diseases
Disease Gene (Protein) Proposed Mechanisma
Hereditary Recurrent Fevers
Familial Mediterranean fever (FMF) MEFV (pyrin) Increased inflammasome activation
TNF receptor-associated periodic syndrome 
(TRAPS)
TNFRSF1A (TNFR1) Protein misfolding
Hyperimmunoglobulinemia D with periodic fever 
syndrome (HIDS)
MVK (mevalonate kinase) Increased inflammasome activation
Familial cold autoinflammatory syndrome (FCAS) NLRP3/CIAS1 (NLRP3/cryopyrin) Intrinsic inflammasomopathy
Muckle-Wells syndrome (MWS) NLRP3/CIAS1 (NLRP3/cryopyrin) Intrinsic inflammasomopathy
Neonatal-onset multisystem inflammatory dis-
ease (NOMID)
NLRP3/CIAS1 (NLRP3/cryopyrin) Intrinsic inflammasomopathy
Idiopathic Febrile Syndromes
Systemic onset juvenile idiopathic arthritis 
(SoJIA)
Complex Unknown
Adult-onset Still’s disease Complex Unknown
Schnitzler syndrome Sporadic? Increased inflammasome activation
Pyogenic Disorders
Pyogenic arthritis with pyoderma gangrenosum 
and acne (PAPA)
PSTPIP1/CD2BP1 (PSTPIP1/CD2BP1) Abnormal PSTPIP1 binding to pyrin causing 
increased IL-1β activation
Granulomatous Diseases
Chronic granulomatous synovitis with uveitis and 
cranial neuropathy (Blau syndrome)
NOD2/CARD15 (NOD2/CARD15) NF-κB activation disorder
Crohn’s disease Complex (NOD2, ATG16L1, IRGM) NF-κB activation disorder
Autoinflammatory Disorders of Skin and Bone
Deficiency in IL-1 receptor antagonist (DIRA) IL1RN (IL-1Ra) Absence of negative regulator of IL-1α and IL-1β
Majeed syndrome LPIN2 (Lipin-2) Unknown
Chronic recurrent multifocal osteomyelitis 
(CRMO)
Complex Unknown
Synovitis acne pustulosis hyperostosis osteitis 
(SAPHO)
Complex Unknown
Metabolic Disorders
Gout (monosodium urate deposition) Complex (SLC2A9/GLUT9, ABCG2) Crystal-induced inflammasome activation
Pseudogout (calcium pyrophosphate dihydrate 
deposition)
Complex Crystal-induced inflammasome activation
Type 2 diabetes mellitus Complex Hyperglycemia-induced inflammasome activation
Complement Disorders
Atypical hemolytic-uremic syndrome (aHUS) CFH (complement factor H), MCP 
(CD46), CFI (complement factor I), CFB 
(complement factor B)
Abnormal regulation of C3b
Age-related macular degeneration Complex, CFH Impaired inactivation of C3b
Vasculitis
Behçet’s disease Complex Unknown
Macrophage Activation Syndromes
Familial hemophagocytic lymphohistiocytosis 
(HLH)
UNC13D (Munc13-4), PRF1 (perforin 1), 
STX11 (syntaxin 11)
Impaired efficacy of cytotoxic T lymphocytes with 
compensatory macrophage activation
Secondary HLH Complex Unknown
Storage Diseases
Gaucher’s disease GBA (acid β-glucosidase) Unknown
Atherosclerosis? Complex Unknown
Fibrosing Diseases
Asbestosis/silicosis Complex Particle-induced inflammasome activation
aFor details, see Masters et al., 2009. Intrinsic inflammasomopathies are disorders of proteins that are part of the inflammasome, whereas extrinsic 
inflammasomopathies are disorders of proteins upstream or downstream of the inflammasome in IL-1 activation. Complex genetics indicates multiple 
genetic loci interacting with environmental factors.
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innate immune system—through which 
caspase-1 and thence IL-1β are activated 
(Martinon et al., 2009; see Review by K. 
Schroder and J. Tschopp in this issue). 
With TNF, IL-1β is one of the major medi-
ators of fever and inflammation in man. 
Several other autoinflammatory diseases 
are caused by extrinsic perturbations of 
inflammasome activity. In addition to 
these so-called inflammasomopathies, 
there are five other provisional molecular 
categories of autoinflammatory disease 
(different from the clinical categories 
in Table 1), including NF-κB activation 
disorders, protein-misfolding disorders, 
complement disorders, cytokine signal-
ing diseases, and macrophage activa-
tion syndromes (Masters et al., 2009).
The convergence of the clinical con-
cept of autoinflammatory disease with 
the basic science of innate immunity 
has been mutually reinforcing. This 
Essay summarizes some of the impor-
tant implications of the discoveries of 
the last decade for clinical medicine 
and will outline several challenges for 
the next decade. Finally, we will revisit 
the original concept of autoinflamma-
tory disease to propose an updated 
definition that reflects the current state 
of knowledge.
Figure 1. IL-1β-Mediated Disorders
Several Mendelian autoinflammatory diseases are 
caused by mutations in genes encoding proteins 
that directly or indirectly regulate interleukin-1β (IL-
1β), an important mediator of fever and inflamma-
tion. The NLRP3 inflammasome is one of the macro-
molecular complexes by which IL-1β is activated in 
monocytes and is comprised of NLRP3, ASC, and 
caspase-1. Several endogenous “danger signals,” 
such as monosodium urate or calcium pyrophos-
phate dihydrate crystals, asbestos, silica, amyloid 
β, and ATP, as well as bacterial toxins, activate the 
NLRP3 inflammasome through pathways that have 
not been well defined but may involve reactive oxy-
gen species (ROS) and cathep sin B. With inflam-
masome activation, caspase-1 (IL-1β-converting 
enzyme) cleaves pro-IL-1β into its biologically ac-
tive form. Secreted IL-1β can act in an autocrine or 
paracrine fashion through the IL-1 receptor. The IL-1 
receptor antagonist (IL-1Ra) is a naturally occurring 
antagonist of the binding of IL-1β to its receptor. 
Through mechanisms that have not been thoroughly 
elucidated, PSTPIP1 and pyrin may influence inflam-
masome activity (Shoham et al., 2003; Chae et al., 
2006; Yu et al., 2007). Mevalonate kinase may also 
modulate inflammasome activity through the Rac1/
PI3K/PKB pathway (Kuijk et al., 2008). Muckle-
Wells syndrome is caused by activating mutations in 
NLRP3 itself and manifests a hive-like skin rash. The 
syndrome of pyogenic arthritis with pyoderma gan-
grenosum and acne (PAPA) is caused by missense 
mutations in PSTPIP1. A typical lesion of pyoderma 
gangrenosum is shown. The hyperimmunoglobuline-
mia D with periodic fever syndrome (HIDS) is caused 
by inactivating mutations in mevalonate kinase. Pa-
tients with HIDS have episodes of fever and a dif-
fuse macular papular rash. The deficiency of the IL-1 
receptor antagonist (DIRA) is caused by recessive 
loss-of-function mutations in IL-1Ra and presents in 
infancy with diffuse pustular skin lesions. Image from 
Aksentijevich et al. (2009), copyright ©2009 Massa-
chusetts Medical Society. All rights reserved. Muta-
tions in pyrin cause familial Mediterranean fever (not 
illustrated here).
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Autoinflammatory Disease in 
Current Medical Practice
Advances in the diagnosis of autoin-
flammatory disease in the last decade 
have been nothing short of breathtaking, 
owing both to the availability of molec-
ular genetic testing and to the greatly 
increased clinical awareness of these 
illnesses. Consequently, diagnoses have 
been established in patients who hereto-
fore were clinical enigmas, in many cases 
ending years of fruitless testing and per-
mitting evidence-based prognostica-
tion and targeted therapy. The case of 
FMF is illustrative, with the availability of 
molecular genetic testing having mark-
edly expanded both the geographical 
and clinical boundaries of the disease. 
Prior to the identification of the caus-
ative gene, FMF was thought to affect 
North African (Sephardi) and Iraqi Jews 
almost to the exclusion of East Euro-
pean Ashkenazi Jews. It is now apparent 
that FMF is quite prevalent among Ash-
kenazi Jews but usually presents with 
milder (although often still debilitating) or 
less frequent attacks than seen in their 
 Sephardi brethren, reflecting the relative 
frequencies of the V726A and M694V 
mutations in the respective populations 
(Aksentijevich et al., 1999). Genetic test-
ing for MEFV mutations has also per-
mitted the recognition of undiagnosed 
cases among Italian, Greek, and other 
“low-risk” Mediterranean populations 
and fewer but still significant numbers 
of cases in many other ethnic groups, 
including East Asians. Given the usually 
excellent responses of FMF patients to 
colchicine prophylaxis, such diagnoses 
are often life-altering. Genetic diagnosis 
is now possible for several monogenic 
autoinflammatory diseases (Table 1).
Equally important, the advances of the 
last decade have dramatically improved 
our understanding of disease pathogen-
esis. One major theme that has emerged 
is the importance of excessive IL-1 sig-
naling in Mendelian autoinflammatory 
diseases. FCAS, NOMID/CINCA, and 
Muckle-Wells syndrome (MWS) are all 
caused by autosomal-dominant or de 
novo activating mutations in cryopyrin/
NLRP3, a key inflammasome protein. 
Relative to healthy controls, peripheral 
blood mononuclear cells from muta-
tion-positive MWS and NOMID patients 
produce increased amounts of IL-1β in 
response to lipopolysaccharide (LPS), 
even in the absence of the second signal 
ATP (Gattorno et al., 2007), and periph-
eral blood leukocytes from FCAS patients 
spontaneously release IL-1β when cul-
tured at 32°C (Brydges et al., 2009), pro-
viding a dramatic in vitro correlate of the 
cold sensitivity these patients exhibit. 
In contrast, patients with the recently 
described deficiency in the IL-1 receptor 
antagonist (DIRA) have recessive loss-
of-function mutations in IL1RN, encod-
ing the IL-1 receptor antagonist (IL-1Ra), 
a physiologic inhibitor of IL-1 signaling 
(Aksentijevich et al., 2009; Reddy et al., 
2009). Whereas patients with NOMID 
present with fever, urticarial rash, epiphy-
seal overgrowth of the long bones, and 
chronic aseptic meningitis, patients with 
DIRA often do not present with fever or 
central nervous system inflammation but 
do manifest a diffuse pustular rash and 
multifocal sterile osteomyelitis. It is at 
once intellectually satisfying to see two 
different molecular lesions in the same 
pathway causing autoinflammation and 
intriguing that the clinical phenotypes 
differ as much as they do. Possibly, the 
nuances could be due to other mole-
cules, such as IL-18, that are activated by 
the inflammasome in the cryopyrinopa-
thies, or to the fact that the IL-1Ra fails to 
inhibit signaling by both IL-1α and IL-1β in 
DIRA. Other autoinflammatory disorders 
with a likely IL-1 connection include FMF 
(Chae et al., 2003, 2006), HIDS (Kuijk et 
al., 2008), and the syndrome of pyogenic 
arthritis with pyoderma gangrenosum 
and acne (PAPA) (Shoham et al., 2003; 
Yu et al., 2007). Figure 1 draws attention 
to the common thread of IL-1 signaling 
among illnesses that, at first glance, 
appear quite different.
Positional cloning and candidate 
gene analyses of patients have provided 
important insights into the monogenic 
autoinflammatory diseases, and these 
discoveries have had immediate and 
dramatic impact on current therapy 
(Goldbach-Mansky et al., 2006; Hoffman 
et al., 2008; Dinarello, 2009; Lachmann 
et al., 2009). Largely through the analy-
sis of mice deficient in Nlrp3, a number 
of other genetically complex conditions 
appear also to share an autoinflammatory 
pathophysiology. Prime examples are 
gout and pseudogout, which are caused 
by deposition of, respectively, mono-
sodium urate (MSU) and calcium pyro-
phosphate dihydrate (CPPD) crystals in 
the joints and adjacent tissues. Whereas 
both MSU and CPPD crystals elicit sub-
stantial caspase-1 activation and IL-1β 
release by normal mouse macrophages 
primed with LPS, this response is almost 
completely abrogated in Nlrp3 knock-
out mice (Martinon et al., 2006). MSU-
induced inflammation is also reduced in 
mice deficient in another inflammasome 
component, Asc, or in the IL-1 receptor, 
or in the IL-1 signal transducer MyD88, 
but not in mice deficient for various Toll-
like receptors (Chen et al., 2006). Several 
other particulates, including asbestos, 
silica, and alum, are also activators of 
the inflammasome in mouse models and 
human leukocytes (Dostert et al., 2008; 
Eisenbarth et al., 2008; Hornung et al., 
2008). Although the predisposing factors 
identified to date in human gout appear 
to be primarily metabolic and renal (Choi 
et al., 2010), early clinical trials of both 
anakinra (recombinant IL-1 receptor 
antagonist) and rilonacept (an IL-1 recep-
tor fusion protein) support an important 
role for IL-1β in the pathophysiology of 
gouty arthritis (So et al., 2007; Terkeltaub 
et al., 2009). Because of the burden that 
common diseases like gout impose on 
the general population, studies such as 
these assume a high priority with poten-
tially broad therapeutic application.
Autoinflammation 2010: Challenges 
for a New Decade
Progress in the study of autoinflamma-
tory diseases appears to be in an expo-
nential growth phase, as today’s discov-
eries pose tomorrow’s questions, many 
of which have direct clinical relevance. 
For the monogenic autoinflammatory 
diseases, three genetic questions stand 
out as particularly important to the cli-
nician because of the frequency with 
which they arise. The first concerns the 
interpretation of positive genetic testing 
for several polymorphic variants of the 
periodic fever loci, including E148Q and 
P369S/R408Q at MEFV, R92Q and P46L 
at TNFRSF1A, and Q703K and V198M 
at CIAS1. All of these variants are pres-
ent at an allele frequency of greater than 
1% in certain populations—for MEFV 
E148Q the allele frequency may be as 
high as 23% among the Japanese (Sugi-
ura et al., 2008), and for NLRP3/CIAS1 
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Q703K 6.5% among Swedes (Verma et 
al., 2008)—and are commonly reported 
among patients with undiagnosed auto-
inflammatory phenotypes. For each of 
these variants, the jury is still out, based 
on either careful epidemiologic data or 
in vitro functional studies, as to whether 
they actually confer a distinct pheno-
type, act as modifiers for other inflam-
matory loci, or are simply coincidental 
bystanders. Because of their frequency, 
the implications are substantial.
The second “frequently asked ques-
tion” concerns FMF in particular and 
is based on the fact that many of the 
patients with colchicine-responsive 
clinical FMF have only a single demon-
strable MEFV mutation, despite thor-
ough scrutiny (Booty et al., 2009; Marek-
Yagel et al., 2009; Ozen, 2009). Although 
this widely confirmed observation is 
based on a clinical definition of FMF that 
includes milder cases than were appre-
ciated 20 years ago, it suggests a more 
complex pattern of inheritance than the 
simple recessive model of the textbooks. 
It also argues that solitary MEFV muta-
tions may confer a biochemical or clini-
cal phenotype by mechanisms yet to be 
elucidated, perhaps in the presence of 
as yet unidentified modifier loci.
A third major genetic issue for the 
clinician is finding an explanation for 
the approximately 60% of patients with 
various autoinflammatory phenotypes 
who do not have mutations in any of the 
known genetic loci. The recent exam-
ples of DIRA (Aksentijevich et al., 2009; 
Reddy et al., 2009) and IL-10 receptor 
deficiencies (Glocker et al., 2009) raise 
the possibility that at least some of 
these individuals will eventually be found 
to have mutations in currently unrec-
ognized autoinflammatory genes. An 
important initiative currently undertaken 
at the NIH is to apply whole-genome 
single-nucleotide polymorphism (SNP) 
analyses to search for areas of homozy-
gosity in patients from consanguineous 
families or isolated populations who are 
more likely to have recessive mutations 
and to perform directed candidate gene 
screening or whole-exome sequenc-
ing in selected other cases. Overall, 
in the NIH cohort alone there are over 
1000 unrelated patients with geneti-
cally unexplained autoinflammatory 
phenotypes who may be a rich source 
of yet additional loci that may deepen 
our understanding of the human innate 
immunome.
Another important and largely 
untouched area is the identification of 
susceptibility loci for complex (polygenic) 
autoinflammatory diseases. There are 
a number of such disorders, including 
Behçet’s disease (Gül, 2005), systemic 
onset juvenile idiopathic arthritis (SoJIA) 
(Allantaz et al., 2007), and the syndrome 
of periodic fever with  aphthous stoma-
titis, pharyngitis, and cervical adenopa-
thy (PFAPA) (Feder and Salazar, 2009). 
These illnesses are much more com-
mon than the monogenic autoinflamma-
tory diseases, at least in certain parts 
of the world. Current thinking among 
human geneticists is that, for many of 
the common complex diseases, the eti-
ology derives from permutations and 
combinations of common variants, each 
of which alone may only confer a small 
risk. Such variants can be detected 
by genome-wide association studies 
(GWAS). Based on the experience with 
GWAS conducted thus far for the clas-
sic autoimmune diseases, it is likely that 
the clinical implications of such studies 
will be more relevant to identifying path-
ways that may be amenable to targeting 
with small molecules or biologics than 
to establishing parameters to diagnose 
or predict disease (Gregersen and Ols-
son, 2009). Alternatively, at least some of 
these genetically complex diseases may 
be due to high-penetrance rare muta-
tions that only account for a few cases 
each (Frazer et al., 2009), in which case 
screening or prediction would be possi-
ble. Of course, the most likely scenario is 
that many of these complex autoinflam-
matory diseases are due to a combina-
tion of the two models, with some cases 
due to low-penetrance common variants 
and others caused by rare high-pene-
trance mutations.
The molecular pathophysiology of the 
autoinflammatory diseases is a topic of 
growing clinical interest. Particularly for 
diseases where a genetic approach has 
been taken, we may know the genes and 
mutations, and we may know the clinical 
phenotypes, but in many cases there is a 
black box between the two. Understand-
ing this connection can have important 
implications for how clinicians think 
about human disease. There are many 
examples. FMF has long been a source 
of fascination because of the extraordi-
narily high carrier frequencies of multiple 
different mutations in Mediterranean and 
Middle Eastern populations, strongly 
suggesting a heterozygote advantage 
for a pathogen endemic to that part of 
the world (Masters et al., 2009). Such 
speculation is further fueled by the fact 
that disease-associated mutations tend 
to cluster around a pocket in the C-ter-
minal domain of pyrin, the FMF protein, 
that may be a binding site for such a 
putative pathogen (Weinert et al., 2009). 
Although purely conjectural at this point, 
the smallpox virus appears a particularly 
attractive candidate binding partner, 
both because of the fact that this dis-
ease probably arose in Africa and was 
common in the ancient Mediterranean 
basin where there was a sufficient popu-
lation density to maintain human-human 
spread of the disease (Hopkins, 1983) 
and because poxviruses produce pro-
teins with the canonical N-terminal pyrin 
domain (an interaction motif named after 
the FMF protein) that are thought to sub-
vert the host innate immune response 
(Johnston et al., 2005). The recent devel-
opment of pyrin knockin mice by our 
laboratory may help to investigate the 
interaction between pyrin and various 
pathogens, although of course not the 
smallpox virus itself.
There are many other questions 
with clinical relevance regarding the 
pathophysiology of autoinflammatory 
disease, some of which relate to sin-
gle diseases, and others that are more 
broadly applicable. In the case of TRAPS, 
it appears that the impaired TNF receptor 
ectodomain cleavage initially described in 
these pages (McDermott et al., 1999) may 
have less of a proinflammatory effect than 
more recently described activation due to 
abnormal receptor trafficking (Lobito et 
al., 2006), and this may have important 
implications for treatment. One major 
issue that cuts across many of these ill-
nesses is understanding what may pro-
voke or exacerbate the autoinflammatory 
phenotype and why. Although the original 
definition alluded to “seemingly unpro-
voked” inflammation, we now know that 
frequently there are triggers. Examples 
include cold exposure in FCAS, childhood 
immunizations in HIDS, physical trauma 
in TRAPS and PAPA syndrome, mechani-
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cal trauma to the skin and gastrointestinal 
tract in DIRA, strenuous physical exer-
tion in FMF, and psychological stress 
and menstrual cycles in several of these 
illnesses. Longer-term gene-environment 
interactions are just beginning to be 
appreciated. One important example is 
the apparent relationship between coun-
try of origin and susceptibility to systemic 
amyloidosis in FMF, with much higher 
risks observed for individuals who have 
spent their early lives in countries with 
high infant mortality rates (Touitou et al., 
2007). For example, Armenians with FMF 
living in Armenia have a much higher risk 
of developing amyloidosis than Armenian-
Americans. Although there are many pos-
sible explanations, one attractive possibil-
ity is that frequent, untreated exposure to 
bacterial infection in early childhood may 
predispose to amyloid deposition upon 
repeated inflammatory episodes later in 
life. Similar geographic variability in sus-
ceptibility to AA amyloidosis has been 
observed in a number of other conditions, 
including juvenile idiopathic arthritis.
Also still a mystery is why the auto-
inflammatory diseases exhibit a relative 
paucity of the usual markers of adap-
tive immunity. Of course, just as we are 
now aware that there are triggers for the 
“seemingly unprovoked” episodes of 
autoinflammation, so too is it clear that 
the adaptive immune system is not totally 
quiescent, as evidenced, for example, by 
the polyclonal hyperglobulinemia that is 
frequently seen in the hereditary recur-
rent fevers. Nevertheless, antinuclear 
antibodies and rheumatoid factors are 
notably absent in patients with autoin-
flammatory disease, despite the recent 
demonstration that the vaccine adju-
vant alum stimulates antibody produc-
tion through its activation of the inflam-
masome and innate immunity (Eisenbarth 
et al., 2008). Perhaps the absence of 
some essential second signal, such as 
the presentation of intracellular antigens 
on apoptotic blebs in SLE (Suber and 
Rosen, 2009), explains the relative lack 
of adaptive immunity in the autoinflam-
matory diseases. Finally, there is a brave 
new world of human biology that is just 
emerging as genetic analysis begins to 
uncover the loci that underlie the com-
plex autoinflammatory diseases and the 
host of disorders, such as ankylosing 
spondylitis and psoriasis, that reside at 
the interface between autoinflamma-
tory and autoimmune (McGonagle and 
McDermott, 2006).
Although nearly any topic regarding the 
treatment of autoinflammatory disease is 
clinically relevant, there are two that are 
particularly exciting, the first concern-
ing IL-1 and the second relating to all of 
the other possible therapeutic targets 
(See also Review by C.A. Dinarello in this 
issue). As previously noted, the spectrum 
of disorders in which the inflammasome 
plays some role has grown rapidly in the 
last 10 years, and perhaps one of the 
most interesting is type 2 diabetes mel-
litus. By mechanisms that have not been 
completely elucidated, hyper glycemia 
may induce IL-1β production by pancre-
atic islet cells, leading to islet cell death, 
decreased insulin production, and a 
diabolical resonance between hyperg-
lycemia and IL-1β production (Maedler 
et al., 2002). A recent paper by Monath 
and colleagues suggests a possible role 
for anakinra, the recombinant IL-1 recep-
tor antagonist, in maintaining glycemic 
control (Larsen et al., 2007), which, if con-
firmed, could have a far-reaching impact 
on the practice of clinical medicine. On 
the other hand, despite the incontrovert-
ible importance of IL-1 in both monogenic 
and complex autoinflammatory diseases, 
other pathways are already apparent 
(Masters et al., 2009; Glocker et al., 2009), 
and it is very likely that additional yet-to-
be-discovered cytokines and pathways 
will also be established in the next 10 
years. A recent treatment of the current 
state of the art suggested five molecular 
categories of autoinflammation besides 
the inflammasomopathies (Masters et 
al., 2009), and preliminary data from a 
recently completed Behçet’s disease 
GWAS at the NIH suggest even further 
heterogeneity. Of course, the attraction 
of approaching these inherited diseases 
from the standpoint of patient cohorts 
with genes to be discovered is that such 
an approach maximizes clinical relevance 
while minimizing investigator bias.
Autoinflammatory Disease 
 Reconsidered: Time for a New 
 Definition?
The initial definition of autoinflammatory 
disease was predicated on two nega-
tives, the lack of apparent provocation for 
inflammation and the absence of high-
titer autoantibodies or antigen-specific T 
cells. It is now clear that neither criterion 
is consistently valid, and it seems inevi-
table that more counterexamples will 
appear as time goes on.
For example, given the fact that the 
molecular lesion in FCAS, MWS, and 
NOMID lowers the threshold for inflam-
masome activation, and given the prolif-
eration of agents now known to stimulate 
the inflammasome, it is likely that the list 
of factors known to precipitate attacks 
of the cryopyrinopathies will continue to 
grow. Of course, this is really no different 
from the classic autoimmune diseases, 
where such factors as sun exposure in 
SLE and cigarette smoking in RA are 
increasingly recognized as contributory. 
Similarly, with the growing appreciation 
of crosstalk between the innate and 
adaptive immune systems, it is likely that 
as autoinflammatory diseases are further 
scrutinized, autoantibodies will be found 
within the hyperglobulinemia already 
documented in some of these illnesses.
In contrast, during the last 10 years 
the association between the autoinflam-
matory diseases and the innate immune 
system has only strengthened, and it is 
thus reasonable to propose a revised 
definition that recognizes this connec-
tion. Simply put, the autoinflammatory 
diseases are clinical disorders marked 
by abnormally increased inflammation, 
mediated predominantly by the cells and 
molecules of the innate immune system, 
with a significant host predisposition. 
Such a definition is broad enough still 
to include the Mendelian diseases that 
initially stimulated the conception of the 
autoinflammatory terminology, as well as 
the complex disorders currently under 
investigation. “Significant host predis-
position” might include both hereditary 
factors and proclivities that are the result 
of gene-environment interactions, and 
such a definition would also recognize 
that there is a continuum between the 
autoinflammatory and the autoimmune.
In medicine as in other branches of 
science, terminology evolves with our 
understanding of underlying causes, and 
thus clinging to the initially proposed def-
inition of autoinflammation in 2010 would 
make no more sense than lumping all 
renal disorders together as “Bright’s dis-
ease.” Given that our conceptualization 
of disease is constrained by the words 
790 Cell 140, March 19, 2010 ©2010 Elsevier Inc.
that we use and how we define them, it is 
critical that our clinical terminology keep 
pace with our science. In this way we can 
continue to recognize and understand 
new patients in the clinic with bona fide 
autoinflammatory phenotypes that may 
be a long way from the recurrent fevers 
that first inspired the term.
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